In an attempt to strengthen its medical device division, Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Abiomed for an upfront payment of US$380 per share, representing a total deal value of US$16.6 B. With the takeover, J&J gains access to Abiomed’s Impella® heart pump platform and pipeline of technologies. J&J's MedTech division is already robust following its prior acquisitions of Orthotaxy, Emerging Implant Technologies and TARIS Biomedical.